AstraZeneca results: H1 and Q2 2026

About this update from Astrazeneca Plc

Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030 CAMBRIDGE, England, July 27, 2026 --( BUSINESS WIRE )--AstraZeneca: Revenue and EPS summary Key performance elements for H1 2026 (Growth numbers at constant exchange rates) Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "In the first half we saw strong performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets, including in the US for Baxfendy, our first-in-class medicine for hypertension. While we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks. We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months. We continue to invest at pace in our transformative technologies, and in our commercial execution to bring our innovative medicines to patients around the globe and drive growth beyond 2030." Guidance AstraZeneca reconfirms Total Revenue and Core EPS guidance3 for FY 2026 at CER, based on the average foreign exchange rates through 2025. The Core Tax rate is expected to be between 18-22% If foreign exchange rates for July 2026 to December 2026 were to remain at the average rates seen in June 2026, it is anticipated that Total Revenue in FY 2026 would benefit from a low single-digit percentage positive impact (unchanged) compared to the performance at CER, and Core EPS growth would be broadly similar (unchanged) to the growth at CER. Results highlights Table 1: Milestones achieved since the prior results announcement Phase III and other registrational data readouts Regulatory approvals Regulatory submissions or acceptances* in major regions Other pipeline updates For recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix document in the financial results section of the AstraZeneca investor relations website: www.astrazeneca.com/investor-relations.html Table 2: Key elements of financial performance: Q2 2026 Corporate and business development Dizal Pharmaceutical Co In July 2026, AstraZeneca entered into an exclusive license agreement with Dizal Pharmaceutical Co (Dizal), Ltd for Zegfrovy (sunvozertinib), a novel oral irreversible EGFR inhibitor for patients with lung cancer. AstraZeneca will acquire worldwide rights to develop and commercialise Zegfrovy , which is approved in the US and China for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. AstraZeneca will make an upfront payment to Dizal of $600m and additional payments of up to $900m upon achievement of specific development, regulatory and sales-related milestones. Additionally, Dizal will receive tiered royalties on the global sales of Zegfrovy . The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory clearances. Sino Biopharmaceutical In July 2026, AstraZeneca and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited, entered into an exclusive licence agreement for the development, manufacturing and commercialisation of CTTQ's PDE3/4 inhibitor, TQC3721, which is being developed for respiratory indications. Sino Biopharmaceutical Limited is eligible to receive an upfront payment of $200m, with additional development, regulatory and sales milestones up to $1.9bn, as well as tiered royalties ranging up to double-digit percentages based on the annual net sales of TQC3721 products. The agreement is subject to customary closing conditions, including regulatory clearances. Sustainability highlights In July 2026, AstraZeneca hosted a call for investors to discuss the latest developments in its Sustainability strategy. A replay of the call is available on astrazeneca.com . Reporting calendar The Company intends to publish its 9M and Q3 2026 results on 30 October 2026. Conference call A conference call and webcast for investors and analysts will begin today, 27 July 2026, at 11:45 UK time. Details can be accessed via astrazeneca.com . Notes To read AstraZeneca's H1 & Q2 2026 Financial Results press release in full, read here . View source version on businesswire.com: https://www.businesswire.com/news/home/20260726929817/en/ Contacts Global Media Relations team [email protected] +44 (0)1223 344 800

View stock analysis, news, and events for Astrazeneca Plc